News | March 16, 2026
First patient dosed in trial of novel drug targeting limb-threatening artery disease
The trial will enroll up to 42 patients in Finland across four cohorts
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Subscribe To Our Newsletter & Stay Updated
